慢性淋巴细胞白血病患者初次免疫接种13价肺炎球菌结合疫苗或23价肺炎球菌多糖疫苗后重复肺炎球菌再接种可改善浆母细胞反应
本研究在14例慢性淋巴细胞白血病(CLL)患者和31例免疫正常对照中,评估既往接种PCV13或PPSV23后重复再接种肺炎球菌疫苗的早期体液反应。CLL患者首次再接种后浆母细胞比例未增加(p=0.13),对照增加(p<0.001);第二次再接种后CLL患者浆母细胞较基线增加(p<0.01)。结论认为CLL患者再接种诱导的早期浆母细胞反应弱于对照,但采用重复接种结合T细胞依赖性结合疫苗的策略可改善反应。
要点
- CLL患者基线均未检出浆母细胞,对照均检出(p<0.001)。
- CLL患者首次PCV13再接种后浆母细胞比例未增加(p=0.13),对照增加(p<0.001)。
- 第二次再接种后CLL患者浆母细胞较基线增加(p<0.01)。
核心结论
- CLL患者肺炎球菌再接种诱导的早期浆母细胞反应弱于免疫正常对照,但采用重复接种结合T细胞依赖性结合疫苗的策略可改善反应。
研究设计与样本
- CLL患者(n=14)和免疫正常对照(n=31)在既往初次免疫(3-6年前)接种PCV13或PPSV23后,接受PCV13再接种;首次再接种8周后,所有CLL患者接受第二次PCV13或PPSV23再接种。
- 通过流式细胞术分析外周血B细胞亚群(包括浆母细胞),时间点为首次和第二次再接种前后。
主要发现
- 基线时CLL患者均未检出浆母细胞,而对照均检出(p<0.001)。
- 首次PCV13再接种后,CLL患者浆母细胞比例未增加(p=0.13),对照增加(p<0.001)。
- 第二次PCV13或PPSV23再接种后,CLL患者浆母细胞较基线增加(p<0.01)。
- 若首次再接种后无明显反应,仅第二次PCV13再接种可增加浆母细胞,而PPSV23再接种则不能。
- 伴有低丙种球蛋白血症及正在/既往接受CLL特异性治疗的患者反应差,对第二次再接种亦反应差。
临床怎么用
- 作者认为,在CLL患者中采用重复接种结合T细胞依赖性结合肺炎球菌疫苗的策略可改善早期浆母细胞反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) show an immune dysfunction with increased risk of infections and poor response to vaccination. Streptococcus pneumoniae is a common cause of morbidity and mortality in CLL patients. In a previous randomized clinical trial, we found a superior immune response in CLL patients receiving conjugated pneumococcal vaccine compared to non-conjugated vaccine. The response to revaccination in CLL patients is scarcely studied. In this study, early humoral response to repeated revaccinations with pneumococcal vaccines was evaluated, by determination of B cell subsets and plasmablast dynamics in peripheral blood. METHOD: CLL patients (n = 14) and immunocompetent controls (n = 31) were revaccinated with a 13-valent pneumococcal conjugate vaccine (PCV13) after previous primary immunization (3-6 years ago) with PCV13 or a 23-valent pneumococcal polysaccharide vaccine (PPSV23). Eight weeks after the first revaccination, all CLL patients received a second revaccination with PCV13 or PPSV23. B cell subsets including plasmablasts were analyzed in peripheral blood by flow cytometry, before and after the first and the second revaccination. RESULTS: None of the CLL patients, but all controls, had detectable plasmablasts at baseline (p < 0.001). After the first revaccination with PCV13, the plasmablast proportions did not increase in CLL patients (p = 0.13), while increases were seen in controls (p < 0.001). However, after a second revaccination with PCV13 or PPSV23, plasmablasts increased compared to baseline also in CLL patients (p < 0.01). If no response was evident after first revaccination, only a second revaccination with PCV13 increased plasmablasts in contrast to PPSV23 revaccination. Patients with hypogammaglobulinemia and ongoing/previous CLL specific treatment responded poorly, also to a second revaccination. CONCLUSION: In CLL patients, pneumococcal revaccination induced minor early plasmablast response compared to controls, but the response improved using a strategy of repeated doses with of conjugated T cell dependent pneumococcal vaccine.
引用
- Kättström M, Uggla B, Tina E, et al. Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia. Vaccine. 2023. PMID: 37061372. doi:10.1016/j.vaccine.2023.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。